Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma

MA. Dimopoulos, D. Coriu, S. Delimpasi, I. Špička, T. Upchurch, B. Fang, R. Talpur, E. Faber, M. Beksac, X. Leleu

. 2024 ; 8 (19) : 5012-5021. [pub] 20241008

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, randomizované kontrolované studie, multicentrická studie, klinické zkoušky, fáze III

Perzistentní odkaz   https://www.medvik.cz/link/bmc24018717

Twice-weekly carfilzomib (27 mg/m2) plus lenalidomide and dexamethasone (KRd27) is a standard of care in relapsed/refractory multiple myeloma (RRMM). Once-weekly carfilzomib regimens have shown clinical benefits with improved patient convenience. This open-label, phase 3, multicenter, randomized study aimed to demonstrate noninferiority of the overall response rate (ORR) for once-weekly carfilzomib (56 mg/m2) plus Rd (KRd56) vs twice-weekly KRd27 in RRMM. A total of 454 patients were randomized (1:1) to receive carfilzomib as once-weekly 30-minute infusions of 56 mg/m2 (KRd56; n = 228) or twice-weekly 10-minute infusions of 27 mg/m2 (KRd27; n = 226). Baseline characteristics were balanced between groups. ORR was 82.5% (95% confidence interval [CI], 76.9-87.2) in the once-weekly group vs 86.3% (95% CI, 81.1-90.5) in the twice-weekly group (risk ratio, 0.954 [95% CI, 0.882-1.032]) and did not meet the threshold for statistical significance of noninferiority (P = .0666). Complete response (CR) or better was obtained in 46.9% of patients in the once-weekly arm and 36.3% in the twice-weekly arm. The proportions of patients who achieved CR and were also assessed negative for minimal residual disease were 21.5% and 18.1%, respectively (odds ratio, 1.235 [95% CI, 0.775-1.970]). Progression-free survival was comparable between groups (hazard ratio, 0.945 [95% CI, 0.617-1.447]). The safety profile was similar for both groups. In conclusion, although statistical significance for noninferiority of ORR was not achieved, the efficacy and safety of once-weekly KRd56 were similar to those of twice-weekly KRd27, and once-weekly KRd56 may be an effective and convenient treatment option for patients with RRMM. This trial was registered at www.ClinicalTrials.gov as #NCT03859427.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24018717
003      
CZ-PrNML
005      
20241024111219.0
007      
ta
008      
241015s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/bloodadvances.2024013101 $2 doi
035    __
$a (PubMed)39024542
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Dimopoulos, Meletios A $u Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
245    10
$a A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma / $c MA. Dimopoulos, D. Coriu, S. Delimpasi, I. Špička, T. Upchurch, B. Fang, R. Talpur, E. Faber, M. Beksac, X. Leleu
520    9_
$a Twice-weekly carfilzomib (27 mg/m2) plus lenalidomide and dexamethasone (KRd27) is a standard of care in relapsed/refractory multiple myeloma (RRMM). Once-weekly carfilzomib regimens have shown clinical benefits with improved patient convenience. This open-label, phase 3, multicenter, randomized study aimed to demonstrate noninferiority of the overall response rate (ORR) for once-weekly carfilzomib (56 mg/m2) plus Rd (KRd56) vs twice-weekly KRd27 in RRMM. A total of 454 patients were randomized (1:1) to receive carfilzomib as once-weekly 30-minute infusions of 56 mg/m2 (KRd56; n = 228) or twice-weekly 10-minute infusions of 27 mg/m2 (KRd27; n = 226). Baseline characteristics were balanced between groups. ORR was 82.5% (95% confidence interval [CI], 76.9-87.2) in the once-weekly group vs 86.3% (95% CI, 81.1-90.5) in the twice-weekly group (risk ratio, 0.954 [95% CI, 0.882-1.032]) and did not meet the threshold for statistical significance of noninferiority (P = .0666). Complete response (CR) or better was obtained in 46.9% of patients in the once-weekly arm and 36.3% in the twice-weekly arm. The proportions of patients who achieved CR and were also assessed negative for minimal residual disease were 21.5% and 18.1%, respectively (odds ratio, 1.235 [95% CI, 0.775-1.970]). Progression-free survival was comparable between groups (hazard ratio, 0.945 [95% CI, 0.617-1.447]). The safety profile was similar for both groups. In conclusion, although statistical significance for noninferiority of ORR was not achieved, the efficacy and safety of once-weekly KRd56 were similar to those of twice-weekly KRd27, and once-weekly KRd56 may be an effective and convenient treatment option for patients with RRMM. This trial was registered at www.ClinicalTrials.gov as #NCT03859427.
650    _2
$a lidé $7 D006801
650    12
$a mnohočetný myelom $x farmakoterapie $x mortalita $7 D009101
650    12
$a dexamethason $x aplikace a dávkování $x terapeutické užití $7 D003907
650    12
$a oligopeptidy $x aplikace a dávkování $x terapeutické užití $7 D009842
650    12
$a lenalidomid $x aplikace a dávkování $x terapeutické užití $7 D000077269
650    12
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $x škodlivé účinky $7 D000971
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a senioři $7 D000368
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a dospělí $7 D000328
650    _2
$a výsledek terapie $7 D016896
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a recidiva $7 D012008
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
655    _2
$a klinické zkoušky, fáze III $7 D017428
700    1_
$a Coriu, Daniel $u Department of Hematology, Fundeni Clinical Institute, Bucharest, Romania $u Department of Haematology, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania $1 https://orcid.org/0000000272516079
700    1_
$a Delimpasi, Sosana $u Department of Hematology and Bone Marrow Transplantation Unit, Evangelismos Hospital, Athens, Greece $1 https://orcid.org/0000000175237510
700    1_
$a Špička, Ivan $u First Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic $1 https://orcid.org/0000000254515283 $7 jn20001103644
700    1_
$a Upchurch, Terry $u Amgen Inc, Thousand Oaks, CA
700    1_
$a Fang, Belle $u Amgen Inc, Thousand Oaks, CA
700    1_
$a Talpur, Rakhshandra $u Amgen Inc, Thousand Oaks, CA
700    1_
$a Faber, Edward $u Oncology Hematology Care, Inc, Cincinnati, OH
700    1_
$a Beksac, Meral $u Hematology, Ankara Liv Hospital, Istinye University, Ankara, Turkey $1 https://orcid.org/0000000317978657
700    1_
$a Leleu, Xavier $u Department of Hematology and Cellular Therapy, CIC U1402 CHU de Poitiers, Poitiers, France $1 https://orcid.org/0000000298224170
773    0_
$w MED00194912 $t Blood advances $x 2473-9537 $g Roč. 8, č. 19 (2024), s. 5012-5021
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39024542 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111213 $b ABA008
999    __
$a ok $b bmc $g 2201529 $s 1230690
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 8 $c 19 $d 5012-5021 $e 20241008 $i 2473-9537 $m Blood advances $n Blood Adv $x MED00194912
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace